Prevention trial for Schizophrenia Spectrum Disorders (SSD)
Official title Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention
ClinicalTrials.gov ID: NCT07743645
What this study is testing
- What it's testing
- The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patterns
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 9 to 19. Healthy volunteers may be eligible.
You may be able to join if
- Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations...
- screening positive for two or more risk factors targeted by the intervention
- Participants and parent(s)/legal guardian(s) agree to participate
- psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks.
You likely can't join if
- Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview
- Current or past antipsychotic medication use to specifically treat a psychotic disorder
- major medical and neurological conditions
- moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments;
- current drug or alcohol use that impacts functioning and study engagement;
- Not able to give assent, permission, or consent.
See the full eligibility criteria
- Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations of biological relatives in the family have or likely have a diagnosis...
- screening positive for two or more risk factors targeted by the intervention
- Participants and parent(s)/legal guardian(s) agree to participate
- psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks.
- Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview
- Current or past antipsychotic medication use to specifically treat a psychotic disorder
- major medical and neurological conditions
- moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments;
- current drug or alcohol use that impacts functioning and study engagement;
- Not able to give assent, permission, or consent.
- Not able to undergo MRI.
The study team makes the final eligibility decision.
Where it's taking place
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 9 years to 19 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.